AstraZeneca will move ahead with a Phase 2 trial of a Targacept depression drug that could lead to a new treatment for Alzheimer's disease.
The drug, known as AZD1446, is the product of a research collaboration between the Winston-Salem-based Targacept (NASDAQ: TRGT) and pharmaceutical giant AstraZeneca (NYSE: AZN). It is thought to act on a kind of receptor in the brain known as a neuronal nicotinic receptor, and the planned trial would test it alongside the existing drug donepezil in patients with mild to moderate Alzheimier's. Donepezil is sold under the brand name Aricept. Read more.